May 19th 2025
The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Drug Solutions Podcast: Drug Manufacturing Technology
April 5th 2022In this episode of the Drug Solutions Podcast, Jennifer Markarian, manufacturing reporter, talks about continuous manufacturing of oral solid-dosage drugs with Lawrence De Belder, executive consultant at Pharmatech Associates, a USP company.